As Biotechnology businesses, AgeX Therapeutics Inc. (NYSEAMERICAN:AGE) and Benitec Biopharma Limited (NASDAQ:BNTC), are affected by compare. This especially applies to their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AgeX Therapeutics Inc. 2 0.00 15.30M -0.29 0.00
Benitec Biopharma Limited 1 0.00 6.26M -0.82 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
AgeX Therapeutics Inc. 663,889,612.08% -109.8% -85.5%
Benitec Biopharma Limited 890,216,154.72% 0% 0%

Insider & Institutional Ownership

Roughly 23.5% of AgeX Therapeutics Inc. shares are owned by institutional investors while 4.11% of Benitec Biopharma Limited are owned by institutional investors. Insiders owned roughly 0.2% of AgeX Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AgeX Therapeutics Inc. 31.39% -12.28% -35.18% -25.45% 0% -2.01%
Benitec Biopharma Limited 26.87% 11.45% -51.43% -39.29% -60.83% -43.33%

For the past year AgeX Therapeutics Inc. has stronger performance than Benitec Biopharma Limited


AgeX Therapeutics Inc. beats Benitec Biopharma Limited on 5 of the 9 factors.

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *